Kode Chemoinformatics’ Post

Our recent publication, analysed 138 breast cancer tissues received from Greece from Greek women with breast cancer, found that certain genetic variations (SNPs) in the IFNG gene, specifically rs1861493, rs1861494, and rs2430561, are linked to a higher risk of breast cancer, especially in the more aggressive luminal B type. These genetic changes were more common in luminal B than in luminal A, helping explain differences in cancer severity. These findings suggest that testing for these IFNG SNPs could help identify patients at higher risk for more aggressive breast cancer. RMIT University, Victoria University.

🔍 Breakthrough in Kidney Cancer Research! 🧬 Researchers have unveiled a groundbreaking protein, TPM3P9, that plays a pivotal role in the progression of aggressive clear cell renal cell carcinoma (ccRCC). This discovery not only illuminates the complex mechanisms behind tumor growth but also opens doors for targeted therapies. Key Findings: - TPM3P9 enhances cancer cell proliferation by disrupting critical splicing processes. - Elevated levels of TPM3P9 correlate with poorer patient survival rates, marking it as a potential prognostic marker. - Targeting TPM3P9 could lead to innovative treatments that restore normal splicing and inhibit tumor growth. This research underscores the importance of microproteins derived from noncoding RNAs in cancer biology. As we delve deeper into these mechanisms, we can pave the way for more effective interventions against renal cancer. 👉 Click to learn more about this significant advancement and its implications for patient care! #CancerResearch #HealthcareInnovation #KidneyCancer #MedicalBreakthroughs #Oncology #Publications #RegulatoryAgencies #TPM3P9 #MarketAccess #MarketAccessToday

Did you know that RoosterBio's specialized media can be applicable to non-MSC primary cell types? hPrCSC-44 cells, originally isolated as a stromal cell line from a prostate cancer, are *also* suited for growth using RoosterNourish™ culture medium according to this recent Cancer Research Communications publication from the lab of Aaron LeBeau, Ph.D., at the University of Wisconsin-Madison. We're thrilled to see investigators successfully turn to our products for ideation and applications beyond what we might readily imagine. 📘 Read the publication: https://lnkd.in/dgffjr4a American Association for Cancer Research #cancerresearch #fibroblasts #cancercells #cellculture #stromalcells #fibroblastmedia #mesenchymalstemcells

Excited to share our latest publication on the prognostic value of miRNAs and telomere maintenance genes in kidney cancer! This work highlights the potential of these biomarkers in improving the understanding and management of kidney cancer prognosis. #KidneyCancer #miRNAs #TelomereBiology #CancerResearch #PrecisionMedicine

🔬 Breakthrough in Cancer Research: NCF-1's Role in Tumor Growth 🚀 A recent study has unveiled the critical function of neutrophil cytosolic factor-1 (NCF-1) in the progression of pancreatic and gastric cancers. Key findings include: - Elevated NCF-1 levels found in pancreatic adenocarcinoma (PDAC) and gastric adenocarcinoma cell lines, as well as patient tissues. - NCF-1 accumulation linked to aggressive tumor behavior, particularly during invasion and metastasis. When silenced, cancer cells underwent apoptosis instead of proliferating, underscoring NCF-1's essential role for cell survival. This research highlights the potential for targeting NCF-1 as a therapeutic strategy to combat these aggressive cancers. Understanding its dual role with reactive oxygen species (ROS) could pave the way for innovative treatments. 🔗 Click to learn more about this promising development! #CancerResearch #GastricCancer #MedicalBreakthroughs #NCF1 #Oncology #PancreaticCancer #Publications #MarketAccess #MarketAccessToday

▶️New Paper Out◀️ I am thrilled to announce the publication of our latest research paper titled: “Comprehensive Analysis of Mutational Features of Colorectal Cancer and Multiple Primary Cancers Including Colorectal Component: Data from the Cancer Genome Atlas”. In this study, subsequent bioinformatic approaches were used to detect characterized genetic mutations, their interactions, role in signaling pathways deregulation, and effect on patient survival rate for patients with primary colorectal cancer (CRC) and those with multiple primary cancers (MPCs) including colorectal component. 🔗 https://lnkd.in/eBZCc4PU #CancerResearch #ColorectalCancer #MutationalAnalysis #TheCancerGenomeAtlas #ResearchPublication #Oncology

Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, with approximately 76,000 new diagnoses in the United States each year. If detected early, Vanderbilt University describes, treatments such as immune checkpoint blockade therapy, which bolsters the body’s anti-tumor immune response, can slow cancerous growth, "yet patients vary in their response to ICB therapy, and the mechanisms that determine responsiveness are not well understood." In a new study, Vanderbilt University Medical Center researchers, including former CRI CLIP Investigator Dr. Jeffrey Rathmell, have identified cancer cell-specific genetic alterations that reprogram the immune “landscape,” thereby driving tumor growth, and discovered a potential new drug target to stop it. Explore: https://bit.ly/4b7MPFb #RCC #KidneyCancer #CancerResearch #Immunotherapy

Proud of our work, which sheds light on the critical role of lactate dehydrogenase B (LDHB) in lung cancer metastasis. We found that silencing LDHB significantly reduces cancer cell migration and invasion by disrupting glutathione (GSH) metabolism. Further, targeting LDHB suppresses lung cancer metastasis in preclinical models. These findings underline LDHB as a promising target to combat metastasis—the leading cause of cancer mortality. 🧬💡 A big "THANK YOU" to Huixiang for leading this project and to all our co-authors and collaborators for their help and contributions. #CancerResearch #Metastasis #LungCancer #Therapeutics #Oncology

I'm excited to attend #ASCO24 and meet the oncology community to share more about Foundation Medicine's high-quality tests and how they can impact treatment decisions for advanced cancer patients. If you would like to connect in person, visit us at Booth 22031 or stop by one of the posters that I will be presenting: ✔ June 2nd: BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy (Abstract 5056; poster board 462). ✔ June 3rd: Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes (Abstract 5614; poster board 485). See also additional abstracts from collaborations with Foundation Medicine here: https://lnkd.in/eDamgjCU

Metformin Slows Colorectal Cancer Growth Using microRNAs: Metformin is the most commonly used therapy for type 2 diabetes since it helps lower blood glucose. Studies have shown metformin may also reduce the risk of some cancers in type 2 diabetes. New research has shown that metformin alters levels of microRNAs that target genes to slow the growth and multiplication of colorectal cancer cells. The researchers suggest their findings could lead to new RNA therapeutics for cancer prevention and treatment. #cancer #oncology #prostatecancer #colorectalcancer #immunotherapy #drugdiscovery #drugdelivery #medicalsciences #pharmaceutics #medicine #research #health